Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis
Phase 2
Terminated
- Conditions
- Cystitis, Interstitial
- Registration Number
- NCT00380783
- Lead Sponsor
- Allergan
- Brief Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- 2
Inclusion Criteria
- Diagnosis of painful bladder syndrome/interstitial cystitis
- Moderate or severe bladder pain
Exclusion Criteria
- Any other uncontrolled disease
- Pregnant or nursing females
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Reduction in daily pain scores
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which AGN 203818 modulates pain pathways in interstitial cystitis?
How does AGN 203818 compare to standard-of-care treatments like Elmiron in managing interstitial cystitis pain?
Which biomarkers correlate with response to AGN 203818 in patients with interstitial cystitis?
What adverse events were observed in the Phase 2 trial of AGN 203818 for interstitial cystitis and how were they managed?
Are there combination therapies involving AGN 203818 and other urological agents for interstitial cystitis?